Ligand Pharmaceuticals - Biopharma's Technology and Capital …
Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 100 partnered commercial and development stage programs.
Ligand Pharmaceuticals Incorporated - Investor Relations
2024年11月7日 · Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.
About Us - Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and tomorrow. We fund the clinical development and commercialization of high-value programs that can improve and extend lives around the world.
Royalty Portfolio - Ligand Pharmaceuticals
Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 100 partnered commercial and development stage programs. The assets in our portfolio include treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten ...
Team - Ligand Pharmaceuticals
Before joining Ligand, Dr. Reeves served as President and Chief Medical Officer of AZTherapies, Inc., a private, late-stage clinical biopharmaceutical company focused on developing drugs for neuroinflammation and severe neurological conditions, including Alzheimer’s and ALS.
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol ...
2019年5月2日 · The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.
Ligand Announces Launch of Pelthos Therapeutics to Accelerate ...
2024年4月3日 · Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.
Ligand Reports Third Quarter 2024 Financial Results and Raises …
Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.
News & Events - Press Releases - Ligand Pharmaceuticals
2024年7月8日 · At Ligand Pharmaceuticals Incorporated, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further ...
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE ...
2024年6月18日 · Ligand will now collect commercial royalties on six products developed with the Pfenex Expression Technology, including Merck’s CAPVAXIVE and VAXNEUVANCE ®, Jazz Pharmaceuticals’ RYLAZE ®, Alvogen’s Teriparatide Injection, and Serum Institute of India’s Pneumosil ® and MenFive ® vaccines. About Ligand Pharmaceuticals
- 某些结果已被删除